Baolingbao Biology Co.,Ltd. (002286.SZ)
- Previous Close
9.34 - Open
8.75 - Bid 10.27 x --
- Ask --
- Day's Range
9.35 - 10.27 - 52 Week Range
5.16 - 10.27 - Volume
57,516,353 - Avg. Volume
14,809,843 - Market Cap (intraday)
3.798B - Beta (5Y Monthly) --
- PE Ratio (TTM)
27.03 - EPS (TTM)
0.38 - Earnings Date --
- Forward Dividend & Yield 0.12 (1.23%)
- Ex-Dividend Date Dec 10, 2024
- 1y Target Est
--
Baolingbao Biology Co.,Ltd. researches and develops, manufactures, and sells a range of functional sugars in China. The company offers prebiotics, such as isomaltooligosaccharides, galactooligosaccharides, fructooligosaccharides, bagasse trisaccharides, and xylooligosaccharides; sugar alcohols and new sugar source products, including erythritol, trehalose, crystalline fructose, alodonose, and maltose; dietary fiber products comprising polydextrose and resistant dextrin; modified, waxy maize, and corn starch products; starch sugar products, including oligomaltose, fructose syrup, solid corn syrup, maltodextrin, and glucose syrup; and animal nutrition products comprising baolekang and fubaokang. Its products are used in various applications, such as dairy products, drinks, snacks, health products and dietary supplements, candy, special food items, chemicals for daily use, and animal nutrition. The company also exports its products. Baolingbao Biology Co.,Ltd. was founded in 1997 and is based in Yucheng, China.
www.blb-cn.comRecent News: 002286.SZ
View MorePerformance Overview: 002286.SZ
Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 002286.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 002286.SZ
View MoreValuation Measures
Market Cap
3.45B
Enterprise Value
3.53B
Trailing P/E
24.58
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.34
Price/Book (mrq)
1.65
Enterprise Value/Revenue
1.39
Enterprise Value/EBITDA
20.08
Financial Highlights
Profitability and Income Statement
Profit Margin
4.63%
Return on Assets (ttm)
3.79%
Return on Equity (ttm)
5.52%
Revenue (ttm)
2.4B
Net Income Avi to Common (ttm)
111.16M
Diluted EPS (ttm)
0.38
Balance Sheet and Cash Flow
Total Cash (mrq)
282M
Total Debt/Equity (mrq)
17.49%
Levered Free Cash Flow (ttm)
13.66M